Table 5. Clonogenic survival CI values for RG7388/Nutlin-3 in combination with cisplatin for the wild-type TP53 ovarian cancer cell lines.
| Cell Line | Combination | CI | CI ED50 | CI ED75 | CI ED90 | CI Ave ED50-90 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| XGI50 | ||||||||||
| 0.25 | 0.5 | 1 | 2 | 4 | ||||||
| A2780 | Nut-3+CDDP | 1.9 | 0.4 | 0.4 | 0.6 | 0.6 | 0.7 | 0.6 | 0.6 | 0.7 |
| RG+CDDP | 1.2 | 1.0 | 1.0 | 1.0 | 0.9 | 1.0 | 1.0 | 0.9 | 1.0 | |
| IGROV-1 | Nut-3+CDDP | 0.4 | 0.5 | 0.7 | ND | ND | 0.2 | 0.4 | 0.9 | 0.5 |
| RG+CDDP | 0.8 | 1.0 | 1.4 | 1.9 | 1.9 | 0.9 | 1.1 | 1.4 | 1.1 | |
| OAW42 | Nut-3+CDDP | 1.8 | 1.0 | 1.0 | ND | ND | 1.1 | 1.0 | 1.0 | 1.0 |
| RG+CDDP | 1.2 | 1.9 | 1.7 | 1.7 | 1.7 | 1.8 | 1.7 | 1.7 | 1.7 | |
The combined treatment was performed at the indicated fixed 1:1 ratios relative to their respective GI50 concentrations. CI values were calculated for each constant ratio combination and at effect levels ED50, ED75 and ED90 from the average of at least three independent experiments. CI Ave ED50-90 represents the average of CI values at effect levels of ED50, ED75 and ED90. CI range: < 0.1 very strong synergism; 0.1-0.3 strong synergism; 0.3-0.7 synergism; 0.7-0.85 moderate synergism; 0.85-0.9 slight synergism; 0.9-1.1 nearly additive; 1.1-1.2 slight antagonism; 1.2-1.45 moderate antagonism; 1.45-3.3 antagonism; 3.3-10 strong antagonism; > 10 very strong antagonism. Synergistic combinations are highlighted in bold font. Nut-3, Nutlin-3; RG, RG7388; CDDP, cisplatin; CI, Combination Index; ND; Not determined.